TuHURA Biosciences, Inc. reported an additional borrowing under its existing revolving credit facility with Parkview Holdings One LLC. The Loan Agreement provides for a maximum loan availability of $50 million and matures on April 21, 2031.
On August 7, 2026, the company drew an additional $650,000 under this facility and expects to use the funds for general corporate purposes. The company notes risks related to its ability to continue drawing under the Loan Agreement and whether available funds will meet its operational and development needs.
TuHURA Biosciences, Inc. reports the creation of a direct financial obligation through an additional borrowing under its existing Loan Agreement with Parkview Holdings One LLC. The agreement provides for a revolving credit facility with a maximum availability of $50 million, maturing on April 21, 2031.
On July 28, 2026, the company drew an additional $1,500,000 under this facility and expects to use the proceeds for general corporate purposes. Management highlights risks related to its ability to meet conditions for future drawdowns, the sufficiency of available funds, and potential conflicts of interest because the lender is an affiliate of the company’s largest stockholder.
TuHURA Biosciences, Inc. is calling a virtual 2026 annual stockholders’ meeting on August 18, 2026, at 9:00 a.m. Eastern Time. Stockholders of record as of June 26, 2026, when 63,682,528 common shares were outstanding, may vote online.
Key items include electing six directors, approving under Nasdaq Listing Rule 5635(d) the issuance of 1,878,287 common shares tied to a fee letter with Parkview Holdings One LLC, advisory votes on executive pay and its future frequency, and ratifying Cherry Bekaert LLP as auditor for 2026.
The proxy describes a majority‑independent board with audit, compensation, and nominating committees, a clawback policy, and an insider trading policy. For 2025, CEO James Bianco received total compensation of $3,987,095 and CFO Dan Dearborn received $1,832,036, combining salary, bonuses and equity awards.
TuHURA Biosciences, Inc. has increased its borrowing under an existing revolving credit facility. The company drew an additional $1,900,000 on June 30, 2026, from a loan agreement with Parkview Holdings One LLC that provides up to $50 million in availability and matures on April 21, 2031.
The new funds are expected to be used for general corporate purposes. The filing also highlights risks that the company may not always meet conditions to draw or maintain the loan and notes that the lender is an affiliate of its largest stockholder, which could create potential conflicts of interest.
TuHURA Biosciences, Inc. is soliciting proxies for its 2026 Annual Meeting of Stockholders to be held virtually on August 18, 2026. Stockholders will vote on election of six directors, ratification of auditors, advisory votes on executive compensation and frequency, and a Nasdaq-related issuance approval of 1,878,287 shares.
Holders of record as of June 26, 2026 are entitled to vote; shares outstanding were 63,682,528 shares as of that record date. The Board unanimously recommends voting FOR the director nominees and the proposals listed in the proxy.
TuHURA Biosciences, Inc. has scheduled its 2026 Annual Meeting of Stockholders to be held virtually on August 18, 2026. This date is more than 30 days after the prior 2025 Special Meeting held on June 23, 2025, which resets shareholder proposal and nomination deadlines.
Stockholder proposals for inclusion in the proxy materials under Rule 14a-8, as well as proxy access director nominations, other proposals, and director nominations under the Bylaws and Rule 14a-19, must be received at the company’s Tampa, Florida principal executive offices by June 27, 2026.
TuHURA Biosciences, Inc. has drawn its first funds under a previously disclosed revolving credit facility. The company received $1,700,000 on May 26, 2026 from a loan agreement with Parkview Holdings One LLC, which provides up to $50 million in borrowing capacity and matures on April 21, 2031. TuHURA plans to use this initial draw for general corporate purposes, giving it additional liquidity to support operations and development activities. The company notes risks that it may be unable to satisfy conditions for future borrowings, that available funds could still be insufficient for its needs, and that the lender is affiliated with its largest stockholder, which may create potential conflicts of interest.
TuHURA Biosciences Chief Executive Officer James A. Bianco reported a bona fide gift of 150,000 shares of TuHURA Biosciences common stock. The shares were transferred on May 28, 2026 and, according to the disclosure, were gifted to adult sons who do not share the same household.
Following this gift, Bianco directly holds 2,173,307 shares of TuHURA Biosciences common stock. Because this was a gift with no sale proceeds, it reflects a personal transfer of ownership rather than a market transaction in the company’s stock.
TuHURA Biosciences, Inc. reported a net loss of $7.5 million for the three months ended March 31, 2026, compared with $6.7 million a year earlier, as it continued to invest in its cancer immunotherapy pipeline.
Research and development expenses rose to $5.2 million, driven by IFx‑2.0 Phase 3 work, TBS‑2025 development and higher headcount, while general and administrative costs were $2.3 million. The company had $6.3 million in cash and cash equivalents and used $4.4 million in operating cash during the quarter.
TuHURA closed earlier equity financings and established a $50 million revolving credit facility with Parkview Holdings One LLC, plus a $50 million at‑the‑market equity program. Management states that existing capital resources and expected credit facility access should fund planned operations into the end of 2028 as it advances IFx‑2.0 and TBS‑2025 through clinical development.